Correction: Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE

نویسندگان

  • S Vaccher
  • A Grulich
  • J McAllister
  • D J Templeton
  • M Bloch
  • A McNulty
  • J Holden
  • I M Poynten
  • G Prestage
  • I Zablotska
چکیده

Vaccher S, Grulich A, McAllister J, et al. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. BMJ Open 2016;6:e012179. The author affiliations are incorrect in this manuscript. Corrected affiliations are given below: Authors S Vaccher, A Grulich, J McAllister, D J Templeton, M Bloch, A McNulty, J Holden, I M Poynten, G Prestage, I Zablotska, on behalf of the PRELUDE Study Team Author affiliations Kirby Institute, UNSWAustralia, Kensington, New South Wales, Australia St Vincent’s Hospital, Darlinghurst, New South Wales, Australia RPA Sexual Health, Sydney Local Health District, Camperdown, New South Wales, Australia Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia Sydney Sexual Health Centre, Sydney, New South Wales, Australia Centre for Population Health, NSW Ministry of Health, North Sydney, New South Wales, Australia

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE

INTRODUCTION Despite a number of HIV prevention strategies, the number of new HIV infections remains high. In Australia, over three-quarters of new HIV diagnoses are in gay and bisexual men (GBM). Pre-exposure prophylaxis (PrEP) has been shown to be effective at preventing new HIV infections in several randomised trials. The PRELUDE study aims to evaluate the implementation of PrEP in healthcar...

متن کامل

Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project

BACKGROUND In Australia, pre-exposure prophylaxis (PrEP) is targeted to individuals at high risk for HIV infection. We describe the HIV risk profile and characteristics of PRELUDE participants, and evaluate the population validity of the sample in representing high-risk gay and bisexual men (GBM) eligible for PrEP. METHODS PRELUDE is an on-going, open-label, single-arm observational study. Pa...

متن کامل

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa

Introduction: Pre-exposure prophylaxis (PrEP) can provide high protection against HIV infection and is a recommended intervention for HIV-negative persons with substantial HIV risk, such as individuals with a partner living with HIV.  Demonstration projects of PrEP have been conducted in diverse settings worldwide to illustrate practical examples of how PrEP can be delivered.  Methods: We evalu...

متن کامل

Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project

Introduction The effectiveness of daily pre-exposure prophylaxis (PrEP) is well established. However, there has been increasing interest in non-daily dosing schedules among gay and bisexual men (GBM). This paper explores preferences for PrEP dosing schedules among GBM at baseline in the PRELUDE demonstration project. Materials and methods Individuals at high-risk of HIV were enrolled in a fre...

متن کامل

Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review

Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection. The use of daily tenofovir/emtricitabine as oral PrEP was found ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 6  شماره 

صفحات  -

تاریخ انتشار 2016